John Carroll University

Carroll Collected
Celebration of Scholarship 2022

Celebration of Scholarship

Spring 2022

“The Role of the Endothelin-1 Pathway in the Disruption of the
Blood Brain Barrier in Neuro-Inflammatory Disease”
Sarah Fallavollita
John Carroll University, sfallavollita22@jcu.edu

Follow this and additional works at: https://collected.jcu.edu/celebration_2022
Part of the Neurosciences Commons

Recommended Citation
Fallavollita, Sarah, "“The Role of the Endothelin-1 Pathway in the Disruption of the Blood Brain Barrier in
Neuro-Inflammatory Disease”" (2022). Celebration of Scholarship 2022. 1.
https://collected.jcu.edu/celebration_2022/1

This Poster is brought to you for free and open access by the Celebration of Scholarship at Carroll Collected. It has
been accepted for inclusion in Celebration of Scholarship 2022 by an authorized administrator of Carroll Collected.
For more information, please contact mchercourt@jcu.edu.

The Role of the Endothelin-1 Pathway in the Disruption of the Blood Brain
Barrier in Neuro-Inflammatory Disease
Sarah Fallavollita
With Evi Paouri, Ph.D. and Dimitrios Davalos, Ph.D. at the Lerner Research Institute at the Cleveland Clinic
Results

Abstract
Multiple sclerosis (MS) is an autoimmune neuro-inflammatory disease characterized by disruption of the blood brain barrier (BBB)
and demyelination of axons. MS does not occur naturally in mice, so a mouse model of the disease called experimental autoimmune
encephalomyelitis (EAE) was used as it produces pathological symptoms like those of MS. In this double-blind experiment, healthy
control mice, EAE mice, and EAE mice treated with bosentan (a drug that blocks the endothelin pro-inflammatory pathway) were
compared based the amount of fibrinogen that leaked into the parenchyma of the spinal cord. Overall, the experiment resulted in a
statistically significant reduction in fibrinogen leakage in the EAE bosentan treated mice compared to the vehicle-treated EAE mice.
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Spinal cords from bosentan-treated EAE mice had significantly
less fibrinogen as compared to both vehicle-treated EAE mice •
(p=0.04) and healthy mice (p=0.01) (Figure 4).
There is a statistically significant increase in fibrinogen leakage
•
from the pre-onset and onset groups to the peak EAE group.
Areas of fibrinogen leakage colocalized with areas in which
microglia had begun to cluster and become activated (Figure 5).

•

Early MS is characterized by BBB disruption leading to T-lymphocyte infiltration and leakage of pro-inflammatory substances (including
fibrinogen) into the central nervous system (CNS) perivascular space, and subsequent axonal demyelination (Davalos et al., 2012)
Endothelin-1 (ET1) is a potent vasoconstrictor and is hypothesized to have proinflammatory effects in neurodegenerative diseases, while
also contributing to reduced cerebral blood flow which is associated with cognitive symptoms of MS (Hostenbach et al., 2019).
Previous research on mice has shown that ET1 participates in autoimmune demyelination in the CNS and promotion of inflammatory
immune responses (Jin et al., 2020).
ET receptors on endothelial cells and microglia suggest this may be a mediator of cellular activation and BBB disruption.
Elevated levels of ET1 were found in MS patients and thought to contribute to cerebral vascular disturbances associated with MS
(Haufschild et al., 2001).
Bosentan competitively binds endothelin receptors A and B (PubChem, 2021).
The pathological characteristics of MS can be modeled in mice with experimental autoimmune encephalomyelitis (EAE).
Thus, we hypothesized that EAE mice treated with bosentan would experience less severe neurodegenerative symptoms characterized by
reduced BBB disruption and fibrinogen leakage.
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Methods
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•
•
•

•
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Discussion

EAE was induced by immunization with a myelin oligopeptide MOG35-55 suspended in complete Freund’s adjuvant.
5 days later, mice started receiving bosentan or xanthan gum vehicle daily (Figure 1).
Progression of EAE was monitored and scored based on severity of physical symptoms; mice were sacrificed at different stages of EAE
development and spinal cords were dissected (Figure 2).
Immunohistochemistry was performed with Cy3 fluorophore-conjugated secondary antibodies for the primary antibodies against fibrinogen
and quantified using ImageJ (Figure 3).
Fluorescent signals was analyzed to confirm that microglial activation coincided with areas of fibrinogen leakage into the perivascular space.
Bosentan-treated and vehicle-treated EAE mice were compared with normal healthy mice and compared using a one-way ANOVA test.

Figure 4. Average percent area of fibrinogen in the spinal cord parenchyma of
mice in each group. Each symbol represents a mouse from the group in which
7-14 spinal cord sections were quantified.

Healthy mice had very low levels of fibrinogen
leakage while in mice with EAE, fibrinogen
leakage correlated with disease progression.
There were significant differences in the average
percent area of fibrinogen in the spinal cord
parenchyma which was observed qualitatively in
the number and size of fibrinogen lesions in the
stained spinal cord sections.
Bosentan, an ET1 antagonist, has been found in
the Davalos lab to ameliorate symptoms of EAE by
diminishing proinflammatory signals and
vasoconstriction of blood vessels in the CNS.
EAE mice treated with bosentan had significantly
less fibrinogen leakage in the peak stages of
disease compared to EAE mice treated only with
the vehicle.
The stained spinal cord sections from EAE mice
treated with bosentan had smaller areas of
fibrinogen leakage than those of EAE mice treated
with the vehicle.
This evidence suggests that bosentan is an
effective drug in reducing the amount of leakage
in the vasculature of the CNS.

Conclusions
•

•

•

Figure 1. Timeline of the treatment process for mice in which EAE was induced with the
MOG oligopeptide, then separated five days later into treatment (bosentan) and control
groups (xanthan gum vehicle).

EAE mice treated with bosentan (a drug which
blocks the ET1 pathway) showed less blood vessel
leakage in the spinal cord as compared to EAE
mice treated with the xanthan gum vehicle alone.
Bosentan was successful in reducing the severity
of BBB disruption in EAE mice suggesting that the
ET1 pathway may be involved in
neuroinflammation and BBB disruption.
Considering the central role of BBB disruption in
the progression of neuroinflammatory diseases,
bosentan may be a promising drug for treatment
of MS patients.
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Figure 3: Schematic of protocol for harvesting spinal cord from mouse, preservation, mounting on slides,
immunohistochemistry staining, imaging, and quantifying the percent area of fibrinogen in each spinal cord
section.
Figure 2. The guidelines for assigning clinical scores to EAE mice according to the severity of
their symptoms. The standard curve shows the general trends of clinical scores over time as the
disease progresses.

Figure 5. Representative images of the stained spinal cord
sections from mice in each group. Nuclei of cells were stained
with DAPI (blue), CY3 fluorophores detected fibrinogen (red),
and GFP detected microglia (green).
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